<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019955</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067334</org_study_id>
    <secondary_id>NCI-99-C-0170</secondary_id>
    <nct_id>NCT00019955</nct_id>
    <nct_alias>NCT00001834</nct_alias>
  </id_info>
  <brief_title>Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)</brief_title>
  <official_title>A Phase II Study to Evaluate Radiofrequency Ablation of Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiofrequency interstitial tissue ablation may kill tumor cells by heating tumors
      to several degrees above body temperature.

      PURPOSE: This phase II trial is studying radiofrequency interstitial tissue ablation to see
      how well it works in treating patients with localized renal cell carcinoma (kidney cancer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the efficacy of radiofrequency interstitial tissue ablation in terms of tumor
           destruction or slowed tumor growth rate in patients with localized renal cell carcinoma.

      Secondary

        -  Assess the toxicity of this treatment regimen in these patients.

      OUTLINE: Patients undergo percutaneous radiofrequency interstitial tumor ablation (RFA).
      Patients are offered laparoscopy-assisted percutaneous RFA in the operating room if their
      tumors are not safely accessible. Intra-operative ultrasound is used to confirm probe
      placement and to monitor treatment delivery. If the target temperature or impedance are not
      reached, treatment is repeated no more than twice. No more than 5 tumors are treated per
      kidney.

      All patients are followed at 2 to 3 months, 6 months, and then at 1 year.

      Patients with tumors greater than 2 cm in diameter are followed every 6 months for up to 5
      years. Patients whose tumors become greater than 3 cm are recommended for surgery and removed
      from study if surgery is performed.

      PROJECTED ACCRUAL: A total of 63 patients will be accrued for this study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thermal ablation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Localized renal cell carcinoma, meeting both of the following criteria:

               -  Enlarging renal tumors on imaging studies over a minimum of 12 months

               -  Tumor size between 0.5-4.0 cm in diameter at time of treatment

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine less than 2.0 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

        Other:

          -  Not pregnant

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specifed

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>McClellan M. Walther, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Urologic Oncology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hwang JJ, Walther MM. Update on minimally invasive approaches to kidney tumors. Curr Urol Rep. 2004 Feb;5(1):13-8. Review.</citation>
    <PMID>14733831</PMID>
  </reference>
  <reference>
    <citation>Pautler SE, Walther MM. Transperitoneal laparoscopic radical nephrectomy for bulky renal tumors. Can J Urol. 2002 Oct;9(5):1653-9; discussion 1660. Review.</citation>
    <PMID>12431330</PMID>
  </reference>
  <reference>
    <citation>Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ. Renal tumors in the Birt-Hogg-Dub√© syndrome. Am J Surg Pathol. 2002 Dec;26(12):1542-52.</citation>
    <PMID>12459621</PMID>
  </reference>
  <reference>
    <citation>Wood BJ, Ramkaransingh JR, Fojo T, Walther MM, Libutti SK. Percutaneous tumor ablation with radiofrequency. Cancer. 2002 Jan 15;94(2):443-51. Review.</citation>
    <PMID>11900230</PMID>
  </reference>
  <reference>
    <citation>Friedman M, Mikityansky I, Kam A, Libutti SK, Walther MM, Neeman Z, Locklin JK, Wood BJ. Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol. 2004 Sep-Oct;27(5):427-34. Epub 2004 Jun 3. Review.</citation>
    <PMID>15383844</PMID>
  </reference>
  <reference>
    <citation>Pautler SE, Pavlovich CP, Mikityansky I, Drachenberg DE, Choyke PL, Linehan WM, Wood BJ, Walther MM. Retroperitoneoscopic-guided radiofrequency ablation of renal tumors. Can J Urol. 2001 Aug;8(4):1330-3.</citation>
    <PMID>11564277</PMID>
  </reference>
  <reference>
    <citation>Kam AW, Littrup PJ, Walther MM, Hvizda J, Wood BJ. Thermal protection during percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol. 2004 Jul;15(7):753-8.</citation>
    <PMID>15231890</PMID>
  </reference>
  <reference>
    <citation>Pacak K, Fojo T, Goldstein DS, Eisenhofer G, Walther MM, Linehan WM, Bachenheimer L, Abraham J, Wood BJ. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst. 2001 Apr 18;93(8):648-9.</citation>
    <PMID>11309443</PMID>
  </reference>
  <results_reference>
    <citation>Hwang JJ, Walther MM, Pautler SE, Coleman JA, Hvizda J, Peterson J, Linehan WM, Wood BJ. Radio frequency ablation of small renal tumors:: intermediate results. J Urol. 2004 May;171(5):1814-8.</citation>
    <PMID>15076283</PMID>
  </results_reference>
  <results_reference>
    <citation>Pavlovich CP, Walther M, Choyke PL, Pautler SE, Chang R, Linehan WM, Wood BJ. Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol. 2002 Jan;167(1):10-5.</citation>
    <PMID>11743264</PMID>
  </results_reference>
  <results_reference>
    <citation>Walther MC, Shawker TH, Libutti SK, Lubensky I, Choyke PL, Venzon D, Linehan WM. A phase 2 study of radio frequency interstitial tissue ablation of localized renal tumors. J Urol. 2000 May;163(5):1424-7.</citation>
    <PMID>10751849</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>stage I renal cell cancer</keyword>
  <keyword>stage II renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

